Frequency of UV-Inducible NRAS Mutations in Melanomas of Patients With Germline CDKN2A Mutations

作者: M. Eskandarpour , J. Hashemi , L. Kanter , U. Ringborg , A. Platz

DOI: 10.1093/JNCI/95.11.790

关键词: CDKN2ADysplastic nevus syndromeCarcinogenesisGermlineMutation frequencyBiologyNeuroblastoma RAS viral oncogene homologDysplastic nevusCancer researchMelanoma

摘要: Background: Germline alterations in cyclin-dependent kinase inhibitor 2A (CDKN2A) are important genetic factors familial predisposition to melanoma. Activating mutations of the NRAS proto-oncogene among most common somatic cutaneous malignant melanomas. We investigated occurrence melanomas and dysplastic nevi individuals with germline CDKN2A mutations. Methods: Genomic DNA was extracted from 39 biopsy samples (including primary melanomas, metastatic nevi) 25 patients six Swedish families a hereditary melanoma who carried also 10 sporadic analyzed using polymerase chain reaction, single-strand conformation polymorphism analysis, nucleotide sequence analysis. Differences mutation frequency between were by chi-square test. All statistical tests two-sided. Results: codon 61, all which either CAA(Gln)-AAA(Lys) or CAA(Gln)-CGA(Arg) mutations, found 95% (20/21) but only 10% (1/10) (P<.001). Multiple activating detected tumor cells different regions individual nine patients. that these retained their metastases. at sites other than 61 present indicating instability this locus. an situ melanoma, suggesting role for such during early development. Conclusions: The high may be result hypermutability phenotype associated development

参考文章(54)
Schlom J, Abrams Si, Hand Ph, Tsang Ky, Mutant ras epitopes as targets for cancer vaccines. Seminars in Oncology. ,vol. 23, pp. 118- 134 ,(1996)
B. Epe, DNA damage profiles induced by oxidizing agents Reviews of Physiology Biochemistry and Pharmacology. ,vol. 127, pp. 223- 249 ,(1995) , 10.1007/BFB0048268
Robert E. Tarone, Kenneth H. Kraemer, Alisa M. Goldstein, Margaret A. Tucker, Shin-Ichi Moriwaki, Hypermutability of UV-treated Plasmids in Dysplastic Nevus/Familial Melanoma Cell Lines Cancer Research. ,vol. 57, pp. 4637- 4641 ,(1997)
C. Aarnoudse, A. van Elsas, D. J. Ruiter, K. M. Krüse, N. K. Hayward, S. F. Zerp, S. van der Flier, P. I. Schrier, Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. American Journal of Pathology. ,vol. 149, pp. 883- 893 ,(1996)
Ulrika Stierner, Anton Platz, Jamileh Hashemi, Takayuki Ueno, Ulrik Ringborg, Johan Hansson, CDKN2A Germ-line Mutations in Individuals with Multiple Cutaneous Melanomas Cancer Research. ,vol. 60, pp. 6864- 6867 ,(2000)
Mathijs Baens, Hugo Degreef, Chris De Wolf-Peeters, Mohammad Reza Ahmadian, Klaus Scheffzek, Marguerite Stas, Louis Libbrecht, Anouk Demunter, Joost J. van den Oord, A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Research. ,vol. 61, pp. 4916- 4922 ,(2001)
Zhongqiu Zhang, Yian Wang, Haris G. Vikis, Leisa Johnson, Gongjie Liu, Jie Li, Marshall W. Anderson, Robert C. Sills, H.L. Hong, Theodora R. Devereux, Tyler Jacks, Kun-Liang Guan, Ming You, Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nature Genetics. ,vol. 29, pp. 25- 33 ,(2001) , 10.1038/NG721
V. Ahrenkiel, P. Guldberg, A. F. Kirkin, A. Birck, J. Zeuthen, P. Thor Straten, Disruption of the MMAC1/PTEN Gene by Deletion or Mutation Is a Frequent Event in Malignant Melanoma Cancer Research. ,vol. 57, pp. 3660- 3663 ,(1997)
Brian G. Gabrielli, Marilyn K. Walters, Pamela M. Pollock, Marina Castellano, Louise M. Down, Nicholas K. Hayward, Peter G. Parsons, Louise E. Sparrow, CDKN2A/p16 Is Inactivated in Most Melanoma Cell Lines Cancer Research. ,vol. 57, pp. 4868- 4875 ,(1997)
Marcia S Brose, Patricia Volpe, Michael Feldman, Madhu Kumar, Irum Rishi, Renee Gerrero, Eugene Einhorn, Meenhard Herlyn, John Minna, Andrew Nicholson, Jack A Roth, Steven M Albelda, Helen Davies, Charles Cox, Graham Brignell, Philip Stephens, P Andrew Futreal, Richard Wooster, Michael R Stratton, Barbara L Weber, None, BRAF and RAS mutations in human lung cancer and melanoma Cancer Research. ,vol. 62, pp. 6997- 7000 ,(2002)